📰 Akouos News
Akouos News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Akouos. Real-time updates on events, politics, business and more.
January 25, 2024
Eli Lilly said its experimental gene therapy restored hearing in a boy born with profound hearing loss. The results for this experimental treatment come three months after Regeneron Pharmaceuticals reported early but encouraging data for its hearing loss gene therapy.
January 23, 2024
The genetic treatment targeted a particular kind of congenital deafness and will soon be tried in children who are younger.
October 28, 2022
Eli Lilly to buy gene therapy company Akouos for $487 million
October 18, 2022
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) Tuesday announced its decision to acquire Akouos, Inc. (AKUS), a developer of viral gene therapies for the treatment of inner ear conditions
October 18, 2022
Eli Lilly is acquiring Akouos on the heels of the biotech receiving FDA permission to begin a clinical trial testing its gene therapy for an inherited form of hearing loss. The deal is Lilly’s second gene therapy acquisition following the 2021 buyout of Prevail Therapeutics.
June 1, 2022
Akouos (NASDAQ:AKUS – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday, Zacks.com reports. According to Zacks, “Akouos, Inc. is a precision genetic medicine company. It develops gene therapies to restore, improve and preserve physiologic hearing. The Company’s product candidate includes AK-OTOF, […]
April 28, 2022
Zacks Investment Research upgraded shares of Akouos (NASDAQ:AKUS – Get Rating) from a sell rating to a hold rating in a research note published on Wednesday, Zacks.com reports. According to Zacks, “Akouos, Inc. is a precision genetic medicine company. It develops gene therapies to restore, improve and preserve physiologic hearing. The Company’s product candidate includes […]
April 20, 2022
Akouos (NASDAQ:AKUS – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Wednesday, Zacks.com reports. According to Zacks, “Akouos, Inc. is a precision genetic medicine company. It develops gene therapies to restore, improve and preserve physiologic hearing. The Company’s product candidate includes AK-OTOF, […]
April 10, 2022
Akouos (NASDAQ:AKUS – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Friday, Zacks.com reports. According to Zacks, “Akouos, Inc. is a precision genetic medicine company. It develops gene therapies to restore, improve and preserve physiologic hearing. The Company’s product candidate includes […]
April 4, 2022
Zacks Investment Research cut shares of Akouos (NASDAQ:AKUS – Get Rating) from a hold rating to a sell rating in a research report report published on Thursday morning, Zacks.com reports. According to Zacks, “Akouos, Inc. is a precision genetic medicine company. It develops gene therapies to restore, improve and preserve physiologic hearing. The Company’s product […]